| Literature DB >> 32933115 |
Khawla Abu Hammour1, Esraa Al-Heyari2, Aya Allan2, Ann Versporten3, Herman Goossens3, Ghayda' Abu Hammour2, Qusai Manaseer4.
Abstract
Background: The Global Point Prevalence Survey (Global-PPS) provides a standardised method to conduct surveillance of antimicrobial prescribing and resistance at hospital level. The aim of the present study was to assess antimicrobial consumption and resistance in a Jordan teaching hospital as part of the Global-PPS network.Entities:
Keywords: antimicrobial agents; resistance; stewardship program
Year: 2020 PMID: 32933115 PMCID: PMC7559208 DOI: 10.3390/antibiotics9090598
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Most common indications for therapeutic antibiotic prescription (CAI and HAI) among adults and children.
| Diagnosis * | Patients (n = 125) | % |
|---|---|---|
| Pneumonia or lower respiratory tract infection | 28 | 22.4 |
| Skin and soft tissue | 18 | 14.4 |
| Upper urinary tract infection | 15 | 12.0 |
| Bone joint infections | 14 | 11.2 |
| Lower urinary tract infection | 11 | 8.8 |
| Intraabdominal sepsis | 6 | 4.8 |
| Other | 6 | 4.8 |
| Gastrointestinal infections | 5 | 4.0 |
| Bacteraemia | 4 | 3.2 |
| Infection of central nervous system | 4 | 3.2 |
* Count on the number of diagnoses treated with at least one antimicrobial.
Overall proportional antibiotic use (ATC J01) for medical, surgery, adult ICU, paediatric ICU, and neonatal ICU patients.
| Overall Proportional Antibiotic Use | Medical Patients | Surgery Patients | Adult ICU Patients | Paediatric ICU Patients | Neonatal ICU Patients |
|---|---|---|---|---|---|
| Other beta-lactams | 46.4% | 62.4% | 34.0% | 50.0% | 7.7% |
| Other antibacterials | 18.2% | 23.9% | 27.7% | 33.0% | 23.1% |
| Penicillins | 14.5% | 7.3% | 12.8% | 38.5% | |
| Sulfonamides and Trimethoprim | 2.1% | ||||
| Macrolides Lincosamides and Streptogramins | 4.5% | 3.7% | 2.1% | 16.7% | |
| Quinolones | 11.8% | 8.5% | |||
| Tetracyclines | 1.8% | 6.4% | |||
| Aminoglycosides | 4.5% | 0.9% | 6.4% | 30.8% |
Figure 1Duration of antimicrobial surgical prophylaxis (SP) in adults (N = 36) and children (N = 5) according to the type of surgical procedure.
Prevalence of key quality indicators for antibiotic prescribing (all patients, ATC code = J01; %).
| Quality Indicator | Overall | Medical | Surgical | ICU |
|---|---|---|---|---|
| Indication recorded | 180 (63.2%) | 60 (54.5%) | 61 (56.0%) | 59 (89.4%) |
| Stop/review date documented | 24 (8.4%) | 8 (7.3%) | 12 (11.0%) | 4 (6.1%) |
| Guidelines missing | 12 (4.2%) | 5 (4.5%) | 7 (6.4%) | 0 (0%) |
| Guideline compliant | 138/187 (73.8%) | 55/65 (84.6%) | 46/76 (60.5%) | 37/46 (80.4%) |
| Intravenous route of administration | 191 (97.0%) | 71 (94.7%) | 85 (98.8%) | 35 (97.2%) |
| Multiple ATB diagnosis * | 72/205 (35.1%) | 28/78 (35.9%) | 22/87 (25.3%) | 22/40 (55.0%) |
| Multiple ATB patient ** | 71 (46.2%) | 27 (36.0%) | 23 (26.7%) | 24 (66.7%) |
| Targeted prescribing *** | 41/191 (21.5%) | 16/90 (17.8%) | 31/51 (25.5%) | 12/50 (24.0%) |
Five patients are not counted as they were not prescribed an antibacterial for systemic use but other antimicrobials. For indication recorded, and stop/review date documented: count at antibiotic (ATC code = J01) level. For where guidelines were missing: count on no guideline for an indication at patient level and diagnosis over total scores for this indicator. For guideline compliance: Count at patient level and diagnosis for compliance equals yes/yes plus no. Intravenous route of administration is calculated at patient level. For combination therapy with >1 antibiotic: if one antibiotic by diagnosis is not compliant, this combination therapy, as a whole, for this diagnosis will be counted as noncompliant. Intravenous route of administration calculated at patient level. * Multiple antibiotics (ATB) diagnosis is defined as receiving more than one antibiotic for a single identified reason to treat at patient level. ** Multiple ATB patient is defined as receiving more than one antibiotic at patient level. *** Targeted prescribing is defined as N antibiotics prescribed based on a microbiological result out of “all therapeutic prescribing for community and healthcare-associated infections” only.
Resistance prevalence based on microbiology data.
| Resistance Type | N Patients | Prevalence (%) |
|---|---|---|
| MRSA | 9 | 7.1 |
| MRCoNS | 4 | 3.2 |
| VRE | 0 | 0.0 |
| ESBL | 5 | 4.0 |
| 3−ceph | 4 | 3.2 |
| CRE | 0 | 0.0 |
| ESBL−NF | 1 | 0.8 |
| CR−NF | 2 | 1.6 |
| Other MDR | 11 | 8.7 |
|
|
|
|
N is the number of patients reported to have received a microbiology-based treatment and prevalence (%) = 100 × (the number of patients reported to have received a microbiology-based treatment/total number of patients (N = 127) receiving a treatment with at least one antibacterial for systemic use (ATC J01) for a community-acquired or healthcare-associated infection). Overall resistance prevalence provides the total number of patients concerned, indicating that some patients were identified with more than one resistant organism with the overall resistance prevalence (%) at hospital level. MRSA = targeting methicillin-resistant Staphylococcus aureus; MRCoNS = targeting methicillin-resistant coagulase-negative staphylococci; VRE = targeting vancomycin-resistant enterococci; ESBL = targeting Enterobacteriales producing extended-spectrum beta-lactamase. 3-ceph = targeting third-generation cephalosporin-resistant Enterobacteriales; Enterobacteriales and either the ESBL status is unknown or another resistance mechanism is present. CRE = targeting carbapenem-resistant Enterobacteriales; ESBL-NF = targeting ESBL-producing nonfermenter Gram-negative bacilli targeting nonfermenters (Pseudomonas aeruginosa, Acinetobacter baumannii, Burkholderia spp., Stenotrophomonas maltophilia) producing extended-spectrum beta-lactamase. CR_NF = targeting carbapenem-resistant nonfermenters (Pseudomonas aeruginosa, Acinetobacter baumannii, Burkholderia spp., Stenotrophomonas maltophilia). Other MDRO = targeting multidrug resistant organisms other than the ones listed above.